Several COVID-19 patients have had severe complications from a surge of activated immune cells in the lungs—known as a "cytokine storm."
In a cytokine storm, the immune system overreacts and damages lung tissue, leading to acute respiratory distress and multi-organ failure.
A team led by Jean-Claude Tardif, director of the Montreal Heart Institute research center and professor of medicine at the University of Montreal, are hoping the drug colchicine will work to moderate the overproduction of immune cells and their activating compounds—called cytokines—in COVID-19 patients.
If it proves to be successful, the drug— which is already used to treat gout and pericarditis (inflammation of the heart membrane), and is readily available and inexpensive—could become a key tool in the pandemic fight.
